Roche’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under two months of age with spinal muscular atrophy (SMA) January 25, 2022February 22, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: Roche’s Evrysdi (risdiplam) granted FDA priority…FDA approves Roche’s Evrysdi for use in babies under…New three-year data for Roche’s Evrysdi (risdiplam)…New data for Roche’s Evrysdi (risdiplam) demonstrate…Positive new data for Roche’s Evrysdi in largest…U.S. FDA grants priority review to Roche’s…
